November 18, 2016 - By Ellis Scott · 0 Comments
The stock of Tesaro Incorporated (NASDAQ:TSRO) registered an increase of 9.81% in short interest. TSRO’s total short interest was 8.98M shares in November as published by FINRA. Its up 9.81% from 8.18 million shares, reported previously. With 985,200 shares average volume, it will take short sellers 9 days to cover their TSRO’s short positions. The short interest to Tesaro Incorporated’s float is 28.39%. About 25 shares traded hands. TESARO Inc (NASDAQ:TSRO) has risen 200.29% since April 18, 2016 and is uptrending. It has outperformed by 195.86% the S&P500.
TESARO, Inc. is an oncology-focused biopharmaceutical company. The company has a market cap of $7.40 billion. The Firm acquires, in-licenses and develops oncology product candidates. It currently has negative earnings. It operates in business of developing and commercializing oncology-focused therapeutics segment.
Insitutional Activity: The institutional sentiment increased to 1.89 in 2016 Q2. Its up 0.34, from 1.55 in 2016Q1. The ratio increased, as 24 funds sold all TESARO Inc shares owned while 36 reduced positions. 34 funds bought stakes while 59 increased positions. They now own 44.90 million shares or 3.32% less from 46.44 million shares in 2016Q1.
Ameriprise Fin last reported 0.01% of its portfolio in the stock. Jasper Ridge Partners L P, a California-based fund reported 4,028 shares. Cim Investment Mangement Inc has 0.12% invested in the company for 3,530 shares. Enterprise Fincl Service accumulated 0% or 100 shares. Swiss Bancshares last reported 48,179 shares in the company. America First Investment Advsr Ltd Llc reported 1,000 shares or 0.04% of all its holdings. Vanguard Group Inc has 2.22M shares for 0.01% of their US portfolio. First Mercantile Trust Company has invested 0.04% of its portfolio in TESARO Inc (NASDAQ:TSRO). Bb Biotech Ag has 3.83% invested in the company for 1.15M shares. Acuta Cap Prtnrs Lc holds 1.21% or 30,000 shares in its portfolio. Rock Springs Mgmt Lp last reported 480,000 shares in the company. Utd Service Automobile Association holds 26,828 shares or 0.01% of its portfolio. Federated Invsts Pa accumulated 381,400 shares or 0.09% of the stock. Hap Trading Ltd Co holds 0.06% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 12,310 shares. Senzar Asset Mngmt Limited Com, a New York-based fund reported 94,300 shares.
Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 6 selling transactions for $4.43 million net activity. 408 shares were sold by Huber Martin H. Jr., worth $44,113 on Wednesday, September 21. 7,000 shares with value of $285,274 were sold by English Edward C on Friday, June 10. The insider Hanke Jeffrey H. sold $2.51M.
Out of 13 analysts covering Tesaro Inc (NASDAQ:TSRO), 11 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 85% are positive. Tesaro Inc has been the topic of 23 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Raymond James initiated the shares of TSRO in a report on Tuesday, September 1 with “Strong-Buy” rating. The firm has “Outperform” rating given on Thursday, January 21 by Wedbush. The rating was maintained by Mizuho with “Buy” on Friday, August 5. The stock has “Outperform” rating given by Wedbush on Friday, August 5. The stock of TESARO Inc (NASDAQ:TSRO) earned “Buy” rating by Citigroup on Thursday, March 17. On Friday, November 4 the stock rating was maintained by FBR Capital with “Outperform”. The firm has “Outperform” rating given on Friday, August 12 by RBC Capital Markets. The firm earned “Buy” rating on Monday, October 10 by Bank of America. RBC Capital Markets maintained TESARO Inc (NASDAQ:TSRO) on Monday, October 10 with “Outperform” rating. The rating was initiated by Leerink Swann with “Outperform” on Monday, August 24.
TESARO, Inc. (TESARO), incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Firm acquires, in-licenses and develops oncology product candidates. The Firm operates in business of developing and commercializing oncology-focused therapeutics segment. The Firm has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
More news for TESARO Inc (NASDAQ:TSRO) were recently published by: Fool.com, which released: “Why Tesaro, Inc. Is Tumbling 10.7% Today” on November 15, 2016. Marketwatch.com‘s article titled: “Tesaro Inc. stock drops 11% after announcing public offering at $135 per share” and published on November 15, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott